ClinicalTrials.gg
CompletedNCT00150462Updated May 2, 2017Results posted

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

A Phase 1 interventional study of Carfilzomib and Dexamethasone in Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma and Hodgkin's Disease, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 419 studies in Waldenstrom Macroglobulinemia with a site in United States — 34 open to participants now, 57 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · United States.

Enrollment
132nd of 365
48 · median 37
Started
2005
with 22 others
Phase 1
140 of 419
13 open now
Registered
136th of 419
by date

Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, this one is the 132nd largest by enrollment of the 365 interventional ones that give a count, is one of 23 that started in 2005, is one of 140 in phase 1, and was the 136th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

34 of the 419 studies in Waldenstrom Macroglobulinemia with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 419 studies in Waldenstrom Macroglobulinemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.

03

Conditions studied

  • Waldenstrom's Macroglobulinemia
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease
  • Multiple Myeloma

Keywords

  • Hematological
  • Proteasome
  • Myeloma
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written in accordance with federal, local, and institutional guidelines
  2. Males and females ≥18 years of age
  3. confirmed diagnosis of one of the hematologic below:

    • Multiple myeloma (MM)
    • Non-Hodgkin's lymphoma (NHL)
    • Waldenström's Macroglobulinemia (WM)
    • Hodgkin's disease (HD)
  4. Subjects who are or relapsed following at least two prior therapies
  5. (ECOG) Performance Status of 0-2
  6. Adequate cardiovascular function without symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction in the previous six months
  7. Adequate hepatic function, with \< 2.0 times the , and (AST) and alanine aminotransferase (ALT) of \< 3.0 times the upper limit of normal
  8. Total white blood cell (WBC) count ≥ 2,000/mm³, (ANC) ≥ 1000/mm³, ≥ 8.0 g/dL, and count ≥ 50,000/mm³

    • Screening ANC should be independent of granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for ≥ 1 week and of pegylated G-CSF for ≥ 2 weeks)
    • Subjects receiving supportive care including erythropoietin, darbepoetin and/or bisphosphonates can continue to do so, but must be transfusion independent; subjects receiving erythropoietic support must remain on the same dose for the first 28 days of study participation
  9. An estimated of ≥ 30 mL/min, calculated using the formula of Cockroft and Gault
  10. Serum creatinine ≤ 2.0 mg/dL
  11. Uric acid, if elevated, must be corrected to within laboratory normal range prior to dosing
  12. Female subjects of must agree to use dual methods of and have a negative serum pregnancy test. Male subjects must use an effective barrier method of contraception throughout the study and for three months following the last dose if sexually active with a female of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating
  2. Subjects who are transfusion dependent
  3. Subjects with NHL or HL who have received therapy in the previous seven days
  4. Subjects with MM or Waldenström's Macroglobulinemia who have received steroid therapy in the previous three weeks, except for MM subjects in the Carfilzomib + DEX Expansion Cohort, where previous treatment with dexamethasone will be allowed. The dose and schedule of administration of dexamethasone will be adjusted to that used in the protocol
  5. Radiation, chemotherapy, or immunotherapy in the previous four weeks, or subjects who, in the judgment of the Investigator, have not recovered from the effects of previous therapy
  6. For the Dose Escalation period, subjects who have received prior radioimmunotherapy with anti-cluster of differentiation (CD)20 monoclonal antibodies such as Bexxar® or Zevalin®; subjects treated with these products will be allowed in the Dose Expansion period
  7. Subjects who have received stem cell transplant therapy
  8. Subjects with NHL or HL who have received autologous stem cell transplant therapy and have within 100 days of therapy
  9. Rituxan therapy within three months before Day 1 unless there is evidence of disease progression
  10. Major surgery within three weeks before Day 1
  11. Congestive heart failure (CHF) ( class III to IV)
  12. Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
  13. Subjects who are known or suspected of having (HIV) infection or who are HIV seropositive
  14. Active hepatitis A, B, or C infection; or positive for ribonucleic acid (RNA) or antigen
  15. Non-hematologic within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer with stable prostate specific antigen (PSA) levels for three years
  16. Subjects with treatment-related myelodysplastic disorder
  17. Subjects with known (active central nervous system [CNS] disease only)
  18. Serious psychiatric or medical conditions that could interfere with treatment
  19. Participation in an therapeutic study within one month prior to Day 1
  20. Significant neurotoxicity (Grade 2 or higher with pain) at the time of study initiation
  21. Concurrent therapy with approved or investigative anticancer therapeutics
  22. Subjects with previous to bortezomib injection
  23. Subjects with to receiving allopurinol
  24. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment
  25. Subjects with known or suspected amyloidosis
  26. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    CFZ 1.2 mg/m²

    Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 2.4 mg/m²

    Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 4.0 mg/m²

    Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 6.0 mg/m²

    Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 8.4 mg/m²

    Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 11.0 mg/m²

    Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 15.0 mg/m²

    Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 20.0 mg/m²

    Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 27.0 mg/m²

    Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 20/27 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.

    Drug: Carfilzomib

  • Experimental
    CFZ 20/27 mg/m² + DEX

    Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Administered as an IV bolus dose

    Also known as: PR-171, Kyprolis

  • Administered orally prior to carfilzomib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs)

    A DLT was defined as any of the following occurring in the first 28 days of study participation: Nonhematologic: * \> Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, or diarrhea) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10ˆ9/L) lasting ≥ 14 days without hematopoietic growth factor support * Febrile neutropenia (ANC \< 1.0 × 10ˆ9/L with a fever ≥ 38.3°C) * Grade 4 thrombocytopenia (platelets \< 25.0 × 10ˆ9/L) or thrombocytopenia associated with bleeding. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0.

    Time frame: 28 days

  2. Maximum Observed Plasma Concentration of Carfilzomib (Cmax)

    Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.

  3. Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)

    Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.

  4. Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib

    Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.

  5. Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib

    Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.

Secondary outcomes

  1. Best Clinical Response to Treatment

    Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows: * Complete response: total resolution of measurable disease parameters. * Partial response: a ≥ 50% resolution without the appearance of new disease. * Stable disease: between \< 50% resolution and ≤ 25% increases in measurable disease parameters without appearance of new disease. * Progressive disease: an increase of \> 25% in measurable disease parameters. Best clinical response is the best response observed from the start of study treatment until disease progression or death.

    Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.

  2. Duration of Response

    Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median duration of response was calculated using the Kaplan-Meier method.

    Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.

  3. Time to Progression

    Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment. Median time to progression was calculated using the Kaplan-Meier method.

    Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.

  4. Progression-free Survival

    Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median progression-free survival was calculated using the Kaplan-Meier method.

    Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.

07

Results

Posted Dec 3, 2015

Participant flow

Adults with with multiple myeloma (MM)-both secretory and nonsecretory, non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), or Waldenström's macroglobulinemia (WM) were eligible for enrollment in this study.

Participant flow — Overall Study
MilestoneCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Started33433438674
Completed00000000011
Not completed33433438663
Withdrew: Disease progression or relapse31212235532
Withdrew: Withdrawal by subject01101201010
Withdrew: Death01000000100
Withdrew: Adverse event00010002010
Withdrew: Physician decision00110000000
Withdrew: Other00000000011

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs)

A DLT was defined as any of the following occurring in the first 28 days of study participation: Nonhematologic: * \> Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, or diarrhea) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10ˆ9/L) lasting ≥ 14 days without hematopoietic growth factor support * Febrile neutropenia (ANC \< 1.0 × 10ˆ9/L with a fever ≥ 38.3°C) * Grade 4 thrombocytopenia (platelets \< 25.0 × 10ˆ9/L) or thrombocytopenia associated with bleeding. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0.

Time frame:
28 days
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs)
participantsCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Number of Participants With Dose-limiting Toxicities (DLTs)10000001101
PrimaryMaximum Observed Plasma Concentration of Carfilzomib (Cmax)
Time frame:
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration of Carfilzomib (Cmax)
ng/mLCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m² (±DEX)
Maximum Observed Plasma Concentration of Carfilzomib (Cmax)—————505.17 ± 485.12142.67 ± 97.22527.50 ± 405.59406.08 ± 517.29390.66 ± 492.92
SecondaryBest Clinical Response to Treatment

Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows: * Complete response: total resolution of measurable disease parameters. * Partial response: a ≥ 50% resolution without the appearance of new disease. * Stable disease: between \< 50% resolution and ≤ 25% increases in measurable disease parameters without appearance of new disease. * Progressive disease: an increase of \> 25% in measurable disease parameters. Best clinical response is the best response observed from the start of study treatment until disease progression or death.

Time frame:
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Reported as:
Number · participants
Best Clinical Response to Treatment
participantsCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Complete Response00000000000
Partial Response00000011220
Minimal Response00000000101
Stable Disease/No Change01121102120
Progressive Disease11102213122
Unknown00100000000
SecondaryDuration of Response

Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median duration of response was calculated using the Kaplan-Meier method.

Time frame:
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Reported as:
Median · days
Duration of Response
daysCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Duration of Response——————308.0 (308.0 to 308.0)176.0 (176.0 to 176.0)225.0 (94.0 to 316.0)NA (NA to NA)NA (NA to NA)
SecondaryTime to Progression

Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment. Median time to progression was calculated using the Kaplan-Meier method.

Time frame:
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Reported as:
Median · days
Time to Progression
daysCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Time to Progression114.0 (114.0 to 114.0)232.0 (57.0 to 407.0)NA (54.0 to 54.0)NA (NA to NA)55.0 (47.0 to 55.0)48.0 (15.0 to 176.0)186.0 (50.0 to 322.0)110.5 (15.0 to 190.0)225.0 (36.0 to 330.0)NA (15.0 to 99.0)49.0 (23.0 to 49.0)
SecondaryProgression-free Survival

Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median progression-free survival was calculated using the Kaplan-Meier method.

Time frame:
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Reported as:
Median · days
Progression-free Survival
daysCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Progression-free Survival114.0 (114.0 to 114.0)232.0 (57.0 to 407.0)NA (54.0 to 54.0)NA (NA to NA)55.0 (47.0 to 55.0)48.0 (15.0 to 176.0)186.0 (50.0 to 322.0)110.5 (15.0 to 190.0)225.0 (36.0 to 330.0)NA (15.0 to 99.0)49.0 (23.0 to 49.0)
PrimaryTime to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)
Time frame:
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Reported as:
Mean · minutes
Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)
minutesCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m² (±DEX)
Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)—————5 ± 06 ± 17 ± 26 ± 216 ± 11
PrimaryArea Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib
Time frame:
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Reported as:
Mean · ng*minute/mL
Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib
ng*minute/mLCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m² (±DEX)
Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib—————4049 ± 36951414 ± 9194911 ± 34953409 ± 39644970 ± 5817
PrimaryArea Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib
Time frame:
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Reported as:
Mean · ng*minute/mL
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib
ng*minute/mLCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m² (±DEX)
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib—————4056 ± 36981420 ± 9224942 ± 34973417 ± 39624997 ± 5812

Adverse events

Collected over From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CFZ 1.2 mg/m²—2/3 (66.7%)3/3 (100%)
CFZ 2.4 mg/m²—1/3 (33.3%)3/3 (100%)
CFZ 4.0 mg/m²—3/4 (75%)4/4 (100%)
CFZ 6.0 mg/m²—2/3 (66.7%)3/3 (100%)
CFZ 8.4 mg/m²—2/3 (66.7%)3/3 (100%)
CFZ 11.0 mg/m²—2/4 (50%)4/4 (100%)
CFZ 15.0 mg/m²—1/3 (33.3%)3/3 (100%)
CFZ 20.0 mg/m²—3/8 (37.5%)8/8 (100%)
CFZ 27.0 mg/m²—4/6 (66.7%)6/6 (100%)
CFZ 20/27 mg/m²—3/7 (42.9%)7/7 (100%)
CFZ 20/27 mg/m² + DEX—2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
Febrile neutropeniaBlood and lymphatic system disorders0/30/31/40/31/30/40/30/80/60/70/4
Hyperviscosity syndromeBlood and lymphatic system disorders0/30/30/40/30/30/41/30/80/60/70/4
PyrexiaGeneral disorders0/30/30/41/30/30/40/30/80/60/70/4
BronchitisInfections and infestations0/30/30/40/31/30/40/30/80/60/70/4
PneumoniaInfections and infestations1/31/31/40/31/30/40/30/80/60/70/4
SepsisInfections and infestations0/31/30/40/30/30/40/30/80/60/70/4
Septic shockInfections and infestations0/30/30/40/31/30/40/30/80/60/70/4
SinusitisInfections and infestations1/30/30/41/30/30/40/30/80/60/70/4
Aspartate aminotransferase increasedInvestigations1/30/30/40/30/30/40/30/80/60/70/4
DehydrationMetabolism and nutrition disorders0/30/30/41/30/30/40/30/80/60/70/4
Most frequent other events
Showing 10 of 228
Most frequent other events
EventCFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEX
AnaemiaBlood and lymphatic system disorders1/33/30/42/30/31/42/34/84/64/74/4
NauseaGastrointestinal disorders2/30/33/41/32/32/43/35/84/63/70/4
FatigueGeneral disorders2/30/33/41/31/33/43/33/83/64/71/4
CoughRespiratory, thoracic and mediastinal disorders0/31/32/41/33/32/41/30/84/63/71/4
ArthralgiaMusculoskeletal and connective tissue disorders0/30/30/41/30/30/41/30/85/60/71/4
ThrombocytopeniaBlood and lymphatic system disorders0/31/33/41/30/31/40/33/83/64/73/4
VomitingGastrointestinal disorders0/30/33/42/31/33/41/32/81/61/70/4
PyrexiaGeneral disorders1/31/33/40/31/31/42/32/83/63/70/4
Vision blurredEye disorders2/30/30/40/30/30/41/31/80/60/70/4
ConstipationGastrointestinal disorders2/30/32/41/32/32/40/34/83/62/70/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)CFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEXTotal
Dose Escalation (Part 1)62.5 ± 17.4769.6 ± 4.8055.3 ± 21.7151.7 ± 6.2061.6 ± 9.1561.3 ± 3.7650.3 ± 12.9960.6 ± 11.9967.6 ± 9.82NA ± NANA ± NA60.6 ± 12.25
Dose Expansion (Part 2)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA66.3 ± 9.2154.3 ± 13.5761.9 ± 11.96
Sex: Female, Male
Sex: Female, Male(Participants)CFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEXTotal
Female0232141222322
Male3111202645126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)CFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEXTotal
African American000010000113
Caucasian3233243766342
Hispanic010000000001
Native American001000010002
Disease Diagnosis
Disease Diagnosis(participants)CFZ 1.2 mg/m²CFZ 2.4 mg/m²CFZ 4.0 mg/m²CFZ 6.0 mg/m²CFZ 8.4 mg/m²CFZ 11.0 mg/m²CFZ 15.0 mg/m²CFZ 20.0 mg/m²CFZ 27.0 mg/m²CFZ 20/27 mg/m²CFZ 20/27 mg/m² + DEXTotal
Multiple Myeloma0302122653428
Non-Hodgkin's Lymphoma3031221212017
Waldenstrom's Macroglobulinemia000000000202
Hodgkin's Disease001000000001
08

Study locations

5 sites
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211-1850, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Weil Medical College of Cornell University
    New York, New York 10021, United States
  • Herbert Irving Comprehensive Cancer Center, Columbia University
    New York, New York 10032, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Sep 2005
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Dec 3, 2015
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00150462
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Sep 2005
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Dec 3, 2015
Last update
May 2, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion